by Pharmacogenomics is the study of how genes affect an individual’s response to medications. It helps determine the right drug, at the right dosage for the right individual. With the advent of precision medicine, pharmacogenomics testing enables physicians to customize treatment plans based on a person’s genetic makeup. This not only improves therapeutic efficacy but also reduces adverse reactions to medications.
The global Pharmacogenomics Market is estimated to be valued at US$ 33079.39 Mn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends
The increased adoption of personalized medicine is one of the key drivers of the pharmacogenomics market growth. With advancements in genomics, scientists are gaining deeper insights into how genetic variations affect an individual’s response to various drugs. Pharmacogenomic testing helps identify genetic markers that can predict drug toxicity risk or therapeutic efficacy. This enables doctors to prescribe the right medication in the right dosage according to the patient’s genetic makeup. This personalized approach has significantly improved clinical outcomes while reducing healthcare costs associated with trial-and-error methods of prescribing medications.
SWOT Analysis
Strength:
– Pharmacogenomics enables targeted treatment based on individual patient’s genetic makeup, increasing drug efficacy and safety.
Weakness:
– Lack of clinical guidelines for incorporating pharmacogenomics into standard medical practice.
– High startup costs associated with testing and implementing pharmacogenomics.
Opportunity:
– Growing demand for personalized medicine is driving the adoption of pharmacogenomics.
– Increasing R&D investments by pharmaceutical companies in pharmacogenomics.
Threats:
– ethical and regulatory challenges around genetic testing and data privacy.
– Reimbursement issues related to pharmacogenomic testing.
Key Takeaways
The global Pharmacogenomics Market Demand is expected to witness high growth over the forecast period of 2023 to 2030. The global Pharmacogenomics Market is estimated to be valued at US$ 33079.39 Mn in 2023 and is expected to exhibit a CAGR of 8.1% over the forecast period 2023 to 2030.
North America currently dominates the market and is expected to continue its dominance over the forecast period due to growing adoption of personalized medicine and presence of key market players in the region.
The key players operating in the pharmacogenomics market include Daimler AG, Ford Motor Company, Renault SA, Ashok Leyland Ltd, VE Commercial Vehicles Limited, Tata Motors Ltd, SML Isuzu Limited, GM Group, Mahindra & Mahindra Ltd, Volkswagen AG, Toyota Motor Corporation and Stellantis NV. These key players are focusing on expanding their product portfolios and geographical presence through collaborations and partnerships to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
